Constrained peptides

Details Constrained peptides Constrained peptides

1994-06-10

2000-08-08

Tsang, Cecilia J.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Cyclic peptides

530326, 530327, 530328, 530329, 514 9, 514 13, 514 14, 514 15, 514 16, C07K 764, C07K 900

Patent

active

061003778

ABSTRACT:
Constrained peptides are disclosed which have cyclic portions that contain biologically active regions linked to two linear extensions that each comprise at least one aromatic-group containing amino acid residue. The constrained peptides of the invention are biologically active.

REFERENCES:
Rudinger, J 'Characteristics of amino acids as components of peptide hormones sequence'in Peptide Hormones, (ed. J.A. PArsons). University Park Press, Baltimore, pp. 1-7, 1976.
Mierke, D. et al., "Cis/Trans Isomers in Cyclic Peptides without N-Substituted Amides", J. Am. Chem. Soc. 1989, 111, 6847-6849.
Nutt, R. et al., "Side Chain Conformations of Somatostatin Analogs When Bound to Receptors", from "Somatostatin", Reichlin, S. Ed., Plenum Publishing Corp., 1987, pp. 83-88.
Pelton, J. et al., "Design and Synthesis of Conformationally Constrained Somatostatin Analogues with High Potency and Specificity for .mu. Opioid Receptors", J. Med. Chem. 1986, 29, 2370-2375.
Rivier, J. et al., "Tyrosylated Analogues of Somatostatin", J. of Med. Chem. 1976, 19(8), 1010-1013.
Taylor, J. et al., "In Vitro and in vivo Inhibition of Human Small Cell Lung Carcinoma (NCI-H69) Growth by a Somatostatin Analogue", Biochem. and Biophys. Res. Comm. 1988, 153(1), 81-86.
Amit et al, Science, vol. 233, Aug. 15, 1986, pp. 747-755.
Saragovi et al, Immunomethods, 1, 5-9 (1992).
Amit, et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 .ANG.Resolution"Science 233: 747-753 (1986).
Bach, et al., "Structural Studies of a Family of High Affinity Ligands for GP.sup.IIb/IIIa "New Adv. Peptidomimetics Small Mol. Design I: 1-26 (1994).
Bjorkman et al., "Structure of the Human Class I Histocompatiblity Antigen, HLA-A2"Nature 329: 506-511 (1987).
Cammarota et al., "Identification of a CD4 Binding Site on the .beta..sup.2 Domain of HLA-DR Molecules", Nature 356: 799-800 (1992).
Carroll et al., "Anti-I-A Antibody Modulation of Lymphocyte Traffic in Hapten-Stimulated Inbred Mice"Immunology 62: 471-475 (1987).
Chen et al., "Design and Synthesis of a CD4 .beta.-turn Mimetic That Inhibits Human Immunodeficiency Virus Envelope Glycoprotein gp120 Binding and Infection of Human Lymphocytes", Proc. Nat'l. Acad. Sci. U.S.A. 89: 5872-5876 (1992).
Clayton et al., "Substitution of Murine for Human CD4 Residues Identifies Amino Acids Critical for HIV-gp120 Binding", Nature 335: 363-366 (1988).
Clayton et al., "Identification of Human CD4 Residues Affecting Class II MHC Versus HIV-1 gp120 Binding", Nature 339 : 548-551 (1989).
Davies and Padlan, "Antibody-Antigen Complexes"Annu. Rev. Biochem.: 439-473 (1990).
Di Blasio et al., "Noncoded Residues as Building Blocks in the Design of Specific Secondary Structures: Symmetrically Disubstituted Glycines and .beta.-Alanine", Biopolymers 33: 1037-1049 (1993).
Doyle and Strominger, "Interaction Between CD4 and Class II MHC Molecules Mediates Cell Adhesion"Nature 330: 256-259 (1987).
Fink et al., "Correlations Between T-Cell Specificity and the Structure of the Antigen Receptor", Nature 321: 219-226 (1986).
Fleury et al., "Mutational Analysis of the Interaction Between CD4 and Class II MHC: Class II Antigens Contact CD4 on a Surface Opposite the gp120-Binding SIte", Cell 66: 1037-1049 (1991).
Habeeb, A. F. S. A, "Reaction of Protein Sulfhydryl Groups with Ellman's Reagent", Methods in Enzymology 25: 457-464 (1972).
Helms and Wetzel, "Proteolytic Excision and in Situ Cyclization of A Bioactie Loop in an REI-RGD Presentation Scaffold", Macromolecular Sciences Dept.
Hruby, "Conformational and Topographical Considerations in the Design of Biologically Active Peptides", Biopolymers 33: 1073-1082 (1993).
Kappler et al., "A T Cell Receptor v.beta.Segment That Imparts Reactivity to a Class II Major Histocompatibility Complex Product", Cell 49: 263-271 (1987).
Konig et al ., "MHC Class II Interaction with CD4 Mediated by a Region Analogous to the MHC Class I Binding Site for CD8", Nature 356: 796-798 (1992).
Leahy et al., "Crystal Structure of a Soluble Form of the Human T Cell Coreceptor CD8 at 2.5 .ANG.Resolution "Cell 68: 1145-1162 (1992).
Levi et al., "A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodeficiency Virus Type 1 In Vitro", Proc. Natl. Acad., Sci. USA 90 : 437-408 (1993).
Lowry et al., "Genetically Restricted Antigen Presentation for Immunological Tolerance and Suppression", Nature 308: 373-374 (1984).
Manning et al., "Design of Cyclic and Linear Peptide Antagonists of Vasopression and Oxytocin: Current Status Future Directions" Reg. Peptides, 45:279-283 (1993).
Marshall et al., "Ch. 24, Peptide Conformation and Biological Activity", Annual Reports in Medicinal Chemistry 13: 227-238 (1978).
Matsuyama et al., "A Novel Extracellular Cyclic Lipopeptide Which Promotes Flagellum-Dependent and -Independent Spreading Growth of Serratia Marcescens", J. Bacteriol. 174: 1769-1776 (1992).
Mazerolles et al., "Regulation of T Helper-B Lymphocyte Adhesion Through CD4-HLA Class II Interaction"Eur. J. Immunol. 20: 637-644 (1990).
Mazerolles, et al., "Immunosuppressive Properties of Synthetic Peptides Derived from CD4 and HLA-DR Antigens"Cell 55:497-504 (1988).
McDonnell et al., "Rational Design of a Peptide Analog of the L3T4 CDR3-like Region"Immunomethods 1: 33-39 (1993).
Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc. 15: 2149-2154 (1963).
Montefiori et al., "Evaluation of Antiviral Drugs and Neutralizing Antibodies to Human Immunodeficiency Virus by a Rapid and Sensitive Microtiter Infection Assay", J. Clin. Microbiol., 26: 231-235 (1988).
Padlan and Kabat, "Modeling of Antibody Combining Sites",Meth. Enzym. 203: 3-45 (1991).
Perry et al., "Conversion of Immunity to Suppression by in Vivo Administration of I-A Subregion-Specific Antibodies", J. Exp. Med., 156: 480-491 (1982).
Pride et al., "Molecular Mimicry of Hepatitis B Surface Antigen by an Anti-Idiotype-Deprived Sythetic Peptide", Proc. Natl. Acad. Sci. USA 89: 11900-11904 (1992).
Ryu et al., "Crystal Structure of an HIV-Binding Recombinant Fragment of Human CD4", Nature 348: 419-426 (1990).
Salter et al., "A Binding Site for the T-Cell Co-Receptor CD8 on the .alpha..sup.3 Domain of HLA-A2", Nature 345: 41-46 (1990).
Saragovi et al., "Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design", Biotechnology 10: 773-778 (1992).
Saragovi, et al., "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region", Science 253:792-795 (1991).
Saragovi and Greene, "Constrained Peptides and Mimetics as Probes of Protein Secondary Structure", Immunomethods 1 : 5-9 (1992).
Sibanda et al., "Conformation of .beta.-Hairpins in Protein Structures", J. Mol. Biol. 206: 759-777 (1989).
Taub et al., "Peptide Sequences from the Hypervariable Regions of Two Monoclonal Anti-idiotypic Antibodies Against the Thyrotropin (TSH) Receptor Are Similar to TSH and Inhibit TSH-Increased cAMP Production in FRTL-5 Thyroid Cells", J. Biol. Chem. 267: 5977-84 (1992).
Taub et al., "A Monoclonal Antibody Against the Platelet FIbrinogen Receptor Contains a Sequence That Mimics a Receptor Recognition Domain in FIbrinogen", J. Biol. Chem. 264: 259-265 (1989).
Tramontano, et al., "Structural Determinants of the Conformations of Medium-Sized Loops in Proetins", Proteins Structure, Fuctions, and Genetics 6: 382-394 (1989).
Wang, et al., "Atomic Structure of a Fragment of Human CD4 Containing Two Immunoglobulin-Like Domain", Nature 348:411-418 1990).
Weiner et al., "Species Tropism of HIV-1 Infectivity of Interspecific Cell Hydribomas Implies Non-CD4 Structures Are Required for Cell Entry", Cancer Detection and Prevention 14: 317-320 (1990).
Weiner et al., "HIV Infectivity: Analysis of Viral Envelope Determinants and Target Cell Requirements for Infectivity by HIV-1", Vaccines 90:339-345 Cold Spring Harbor Laboratory Press (1990).
Welling et al., "A Ten-Residue Fragment of an Antibody (Mini-Antibody) Directed Against Lysozyme as Ligand in Immunoaffinity Chromatography", J. Chromatography 548: 235-

Affiliated with

Also associated with

Rating

Constrained peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Constrained peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Constrained peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1151099